Overview A Study to Evaluate the Efficacy and Safety of AD-218 Status: Not yet recruiting Trial end date: 2024-10-31 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the efficacy and safety of AD-218 Phase: Phase 3 Details Lead Sponsor: Addpharma Inc.